LLY

1,050.33

+2.41%↑

JNJ

202.06

+1.48%↑

ABBV

235

+0.74%↑

UNH

305.15

-1.35%↓

AZN

89.32

+0.9%↑

LLY

1,050.33

+2.41%↑

JNJ

202.06

+1.48%↑

ABBV

235

+0.74%↑

UNH

305.15

-1.35%↓

AZN

89.32

+0.9%↑

LLY

1,050.33

+2.41%↑

JNJ

202.06

+1.48%↑

ABBV

235

+0.74%↑

UNH

305.15

-1.35%↓

AZN

89.32

+0.9%↑

LLY

1,050.33

+2.41%↑

JNJ

202.06

+1.48%↑

ABBV

235

+0.74%↑

UNH

305.15

-1.35%↓

AZN

89.32

+0.9%↑

LLY

1,050.33

+2.41%↑

JNJ

202.06

+1.48%↑

ABBV

235

+0.74%↑

UNH

305.15

-1.35%↓

AZN

89.32

+0.9%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.03 7.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.96

Max

1.04

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	5.5M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+418.63% upside

Turustatistika
By TradingEconomics
Turukapital	-13M 112M
Eelmine avamishind	-6.26
Eelmine sulgemishind	1.03

Uudiste sentiment

By Acuity

35%

65%

128 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. nov 2025, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- 2nd Update

18. nov 2025, 18:09 UTC

Omandamised, ülevõtmised, äriostud

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- Update

18. nov 2025, 17:39 UTC

Omandamised, ülevõtmised, äriostud

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough

18. nov 2025, 16:25 UTC

Suurimad hinnamuutused turgudel

Diginex Rises on Deal With Digital Asset Platform Evident

18. nov 2025, 23:56 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

18. nov 2025, 23:39 UTC

Market Talk

Nikkei May Rise on Bargain-Hunting Interest -- Market Talk

18. nov 2025, 22:59 UTC

Market Talk

FireFly Metals Can Build Bigger Operation at Green Bay -- Market Talk

18. nov 2025, 22:08 UTC

Market Talk

Sandfire's Kalkaroo Project Push Adds to Copper M&A Surge -- Market Talk

18. nov 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Meta Defeats FTC's Antitrust Case Alleging Social-Media Monopoly -- 3rd Update

18. nov 2025, 22:03 UTC

Tulu

These Stocks Moved the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18. nov 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. nov 2025, 21:15 UTC

Market Talk

Private High-Grade Credit Market Is Changing, BlackRock Says -- Market Talk

18. nov 2025, 20:46 UTC

Market Talk

U.S. Natural Gas Futures Edge Up on Weather Outlook -- Market Talk

18. nov 2025, 20:13 UTC

Market Talk

Distillate Supply Concerns Pull Crude Futures Higher -- Market Talk

18. nov 2025, 19:48 UTC

Market Talk

Gold and Silver Turn Lower on Fed Outlook -- Market Talk

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Anheuser-Busch InBev Nears $700 Million Deal for Party Punch Maker BeatBox -- WSJ

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Anheuser-Busch InBev in Talks to Buy Party Punch Maker BeatBox, Sources Say -- WSJ

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

AB InBev-BeatBox Deal Could Come Together Soon, Sources Say -- WSJ

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

AB InBev Deal Would Value BeatBox At Around $700M, Sources Say -- WSJ

18. nov 2025, 18:29 UTC

Tulu

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18. nov 2025, 18:18 UTC

Market Talk

Ethanol Demand Expected to Boost Corn Futures -- Market Talk

18. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

18. nov 2025, 17:19 UTC

Market Talk

Tulu

Good Weather Was Bad News for Home Depot's 3Q -- Market Talk

18. nov 2025, 17:06 UTC

Tulu

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18. nov 2025, 16:06 UTC

Omandamised, ülevõtmised, äriostud

Intuit Stock Gains on OpenAI Deal. ChatGPT Is Coming to TurboTax. -- Barrons.com

18. nov 2025, 15:59 UTC

Tulu

Home Depot Cuts Outlook as Home Improvement Slowdown Continues -- Update

18. nov 2025, 15:35 UTC

Omandamised, ülevõtmised, äriostud

Eni: Acquisition Adds to Plenitude's Installed-Capacity Targets, Bolsters France Presence

18. nov 2025, 15:35 UTC

Omandamised, ülevõtmised, äriostud

Eni: Portfolio Comprises Capacity of Around 760MW in Operation

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

418.63% tõus

12 kuu keskmine prognoos

Keskmine 5.29 USD 418.63%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

128 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.